ALGS Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc. develops targeted, curative therapies for hepatologic diseases and viral infections. It engages in building a pipeline of drug candidates which targets multiple clinically validated mechanisms of action and are designed to achieve functional cure for CHB and become transformative treatment options for COVID-19 and NASH. The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.

$12.67  -0.37 (-2.84%)
As of 12/06/2021 15:59:31 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  10/16/2020
Outstanding shares:  42,608,792
Average volume:  142,561
Market cap:   $555,618,648
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    01626L105
ISIN:        US01626L1052
Sedol:      BNGFS94
Valuation   (See tab for details)
PE ratio:   -4.32
PB ratio:   2.49
PS ratio:   -84.75
Return on equity:   -57.62%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy